BRPI0815097A2 - agonistas de receptor acoplado à proteína g gpr119 de piridona - Google Patents

agonistas de receptor acoplado à proteína g gpr119 de piridona

Info

Publication number: BRPI0815097A2
Authority: BR; Brazil
Prior art keywords: gpr119; pyridone; protein; receptor agonists; coupled receptor
Prior art date: 2007-07-17

Application number

BRPI0815097A

Other languages

English (en)

Inventor

A. Wacker Dean

A. Rossi Karen

Wang Ying

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-17

Filing date

2008-07-16

Publication date

2018-07-24

2008-07-16 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2018-07-24 Publication of BRPI0815097A2 publication Critical patent/BRPI0815097A2/pt

Links

LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)

BRPI0815097A 2007-07-17 2008-07-16 agonistas de receptor acoplado à proteína g gpr119 de piridona BRPI0815097A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95016207P	2007-07-17	2007-07-17
PCT/US2008/070101 WO2009012275A1 (en)	2007-07-17	2008-07-16	Pyridone gpr119 g protein-coupled receptor agonists

Publications (1)

Publication Number	Publication Date
BRPI0815097A2 true BRPI0815097A2 (pt)	2018-07-24

Family

ID=39864683

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0814428-1A2A BRPI0814428A2 (pt)	2007-07-17	2008-07-16	Método para modular o receptor acoplado à proteína g gpr119 e compostos selecionados
BRPI0815097A BRPI0815097A2 (pt)	2007-07-17	2008-07-16	agonistas de receptor acoplado à proteína g gpr119 de piridona

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814428-1A2A BRPI0814428A2 (pt)	2007-07-17	2008-07-16	Método para modular o receptor acoplado à proteína g gpr119 e compostos selecionados

Country Status (27)

Country	Link
US (6)	US8003796B2 (pt)
EP (2)	EP2170864B1 (pt)
JP (3)	JP5301539B2 (pt)
KR (2)	KR20100045471A (pt)
CN (3)	CN101801956B (pt)
AR (2)	AR067568A1 (pt)
AT (2)	ATE540945T1 (pt)
AU (2)	AU2008276057B2 (pt)
BR (2)	BRPI0814428A2 (pt)
CA (2)	CA2693439A1 (pt)
CL (2)	CL2008002111A1 (pt)
CO (1)	CO6160315A2 (pt)
CY (2)	CY1112151T1 (pt)
DK (2)	DK2170864T3 (pt)
EA (2)	EA016595B1 (pt)
ES (2)	ES2371515T3 (pt)
HK (2)	HK1136298A1 (pt)
HR (2)	HRP20110806T1 (pt)
IL (1)	IL228120A0 (pt)
NZ (2)	NZ582664A (pt)
PE (2)	PE20090449A1 (pt)
PL (2)	PL2170864T3 (pt)
PT (2)	PT2170864E (pt)
SI (2)	SI2170864T1 (pt)
TW (2)	TW200904440A (pt)
WO (2)	WO2009012277A1 (pt)
ZA (2)	ZA201000151B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101111480A (zh) *	2004-12-01	2008-01-23	万有制药株式会社	取代的吡啶酮衍生物
CN101668756A (zh)	2007-05-04	2010-03-10	百时美施贵宝公司	[6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
SI2170864T1 (sl)	2007-07-17	2012-04-30	Bristol Myers Squibb Co	Piridon gpr119g proteinsko povezani receptorski antagonisti
EP2146210A1 (en)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN102099036B (zh)	2008-06-03	2015-05-27	英特芒尼公司	用于治疗炎性疾患和纤维化疾患的化合物和方法
CN102159572A (zh) *	2008-07-16	2011-08-17	先灵公司	双环杂环衍生物及其作为gpr 119调节剂的用途
TW201006821A (en) *	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
EP2324036B1 (en) *	2008-07-16	2014-12-03	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en)	2009-03-12	2009-04-22	Prosidion Ltd	Compounds for the treatment of metabolic disorders
JP2012520868A (ja) *	2009-03-20	2012-09-10	ファイザー・インク	３−オキサ−７−アザビシクロ［３．３．１］ノナン
TW201113269A (en)	2009-06-24	2011-04-16	Boehringer Ingelheim Int	New compounds, pharmaceutical composition and methods relating thereto
MX2011013648A (es)	2009-06-24	2012-03-06	Boehringer Ingelheim Int	Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
CA2795732A1 (en)	2010-04-08	2011-10-13	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
EP2566862B1 (en)	2010-05-06	2015-09-16	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
EA201270778A1 (ru)	2010-05-06	2013-04-30	Бристол-Майерс Сквибб Компани	Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8785463B2 (en)	2010-10-08	2014-07-22	Cadila Healthcare Limited	GPR 119 agonists
EP3469907B1 (en)	2010-12-06	2021-03-03	Aclaris Therapeutics, Inc.	Substituted pyridinone-pyridinyl compounds
US9359300B2 (en)	2010-12-06	2016-06-07	Confluence Life Sciences, Inc.	Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP2686312B1 (en) *	2011-03-14	2016-08-31	Boehringer Ingelheim International GmbH	N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
JP6463631B2 (ja)	2011-06-09	2019-02-06	ライゼン・ファーマシューティカルズ・エスアー	Ｇｐｒ−１１９のモジュレータとしての新規化合物
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9174965B2 (en)	2012-05-16	2015-11-03	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
AU2013290100A1 (en)	2012-07-11	2015-01-29	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092742A1 (es) *	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
PL2921489T3 (pl) *	2012-11-13	2018-01-31	Nissan Chemical Ind Ltd	Związek 2-pirydonu
CN102993088A (zh) *	2012-12-31	2013-03-27	东华大学	一种4-羟基-2-吡啶酮的制备方法
TW201444849A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh)	2013-03-13	2018-04-21	比利時商健生藥品公司	經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
HUE054178T2 (hu)	2013-06-07	2021-08-30	Aclaris Therapeutics Inc	Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek
ES2761571T3 (es)	2013-06-20	2020-05-20	Bayer Cropscience Ag	Derivados de arilsulfuro y arilsulfóxido como acaricidas e insecticidas
BR112015031155A2 (pt)	2013-06-20	2017-07-25	Bayer Cropscience Ag	derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas
EP3019481B1 (de)	2013-07-08	2019-03-06	Bayer CropScience Aktiengesellschaft	Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
CA2943363A1 (en)	2014-04-02	2015-10-08	Intermune, Inc.	Anti-fibrotic pyridinones
EP2929883A1 (en)	2014-04-08	2015-10-14	Institut Pasteur	Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
BR112017004742B1 (pt)	2014-09-11	2022-11-29	Janssen Pharmaceutica Nv	2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina
WO2016130652A1 (en)	2015-02-10	2016-08-18	Vanderbilt University	Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) *	2015-03-25	2019-09-18	公益財団法人相模中央化学研究所	一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en)	2017-11-03	2020-12-15	Fondazione Istituto Italiano Di Tecnologia	Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
JP2023519891A (ja)	2020-03-27	2023-05-15	アクラリスセラピューティクス，インコーポレイテッド	置換ピリジノン－ピリジニル化合物のプロセス、組成物、および結晶形態
UY39222A (es)	2020-05-19	2021-11-30	Kallyope Inc	Activadores de la ampk
EP4172162A1 (en)	2020-06-26	2023-05-03	Kallyope, Inc.	Ampk activators
WO2022081573A1 (en) *	2020-10-12	2022-04-21	University Of Tennessee Research Foundation	Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) *	2022-08-15	2022-12-23	广西中医药大学	4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3826643A (en) *	1967-08-07	1974-07-30	American Cyanamid Co	Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) *	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en) *	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5491134A (en) *	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) *	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) *	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) *	1996-08-07	2003-05-20	Darwin Discovery Ltd.	Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
WO2000001389A1 (en)	1998-07-06	2000-01-13	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2348740A1 (en)	1998-12-23	2000-07-06	Ruth R. Wexler	Thrombin or factor xa inhibitors
WO2002002519A2 (en)	2000-06-29	2002-01-10	Bristol-Myers Squibb Pharma Company	THROMBIN OR FACTOR Xa INHIBITORS
DE60125227T2 (de)	2000-12-01	2007-09-20	Astellas Pharma Inc.	Verfahren zum screening von diabetes-heilverfahren
WO2003059884A1 (en) *	2001-12-21	2003-07-24	X-Ceptor Therapeutics, Inc.	Modulators of lxr
US7482366B2 (en)	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
GEP20063937B (en) *	2002-02-14	2006-10-10	Pharmacia Corp	Substituted pyridinones as modulators of p38 map kinase
KR101078098B1 (ko)	2003-01-14	2011-10-28	아레나 파마슈티칼스, 인크.	대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
PT1606282E (pt)	2003-02-24	2009-02-10	Arena Pharm Inc	Derivados de fenilo e piridilpiperidina como moduladores do metabolismo da glucose
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
US7003597B2 (en) *	2003-07-09	2006-02-21	International Business Machines Corporation	Dynamic reallocation of data stored in buffers based on packet size
UA86943C2 (ru) *	2003-07-11	2009-06-10	Арена Фармасьютикалз, Инк.	Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS20060018A (en) *	2003-07-14	2007-12-31	Arena Pharmaceuticals Inc.,	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20070088163A1 (en)	2003-09-12	2007-04-19	Kemia, Inc.	Modulators of calcitonin and amylin activity
WO2005085200A1 (ja) *	2004-03-05	2005-09-15	Banyu Pharmaceutical Co., Ltd.	ピリドン誘導体
EP2057996A3 (en)	2004-03-17	2009-11-04	7TM Pharma A/S	Y4 selective receptor agonists for therapeutic intervention
PL1756096T3 (pl) *	2004-05-03	2010-01-29	Hoffmann La Roche	Pochodne indolilowe jako modulatory wątrobowych receptorów X
DE602005011279D1 (de)	2004-06-04	2009-01-08	Arena Pharm Inc	Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
WO2006067532A1 (en)	2004-12-24	2006-06-29	Prosidion Ltd	G-protein coupled receptor agonists
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20060292073A1 (en) *	2005-06-23	2006-12-28	Emory University	Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging
EP1907384A2 (en)	2005-06-30	2008-04-09	Prosidion Limited	Gpcr agonists
JP5114395B2 (ja) *	2005-06-30	2013-01-09	プロシディオン・リミテッド	Ｇｐｃｒアゴニスト
US8093257B2 (en) *	2007-05-04	2012-01-10	Bristol-Myers Squibb Company	[6,5]-bicyclic GPR119 G protein-coupled receptor agonists
CN101668756A (zh) *	2007-05-04	2010-03-10	百时美施贵宝公司	[6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
SI2170864T1 (sl) *	2007-07-17	2012-04-30	Bristol Myers Squibb Co	Piridon gpr119g proteinsko povezani receptorski antagonisti

2008
- 2008-07-16 SI SI200830464T patent/SI2170864T1/sl unknown
- 2008-07-16 TW TW097127046A patent/TW200904440A/zh unknown
- 2008-07-16 PE PE2008001197A patent/PE20090449A1/es not_active Application Discontinuation
- 2008-07-16 EA EA201000211A patent/EA016595B1/ru not_active IP Right Cessation
- 2008-07-16 WO PCT/US2008/070103 patent/WO2009012277A1/en active Application Filing
- 2008-07-16 EP EP08781867A patent/EP2170864B1/en not_active Not-in-force
- 2008-07-16 PL PL08781867T patent/PL2170864T3/pl unknown
- 2008-07-16 CA CA2693439A patent/CA2693439A1/en not_active Abandoned
- 2008-07-16 KR KR1020107003332A patent/KR20100045471A/ko not_active Application Discontinuation
- 2008-07-16 SI SI200830592T patent/SI2173737T1/sl unknown
- 2008-07-16 NZ NZ582664A patent/NZ582664A/en not_active IP Right Cessation
- 2008-07-16 CN CN2008801081672A patent/CN101801956B/zh not_active Expired - Fee Related
- 2008-07-16 US US12/173,856 patent/US8003796B2/en active Active
- 2008-07-16 JP JP2010517123A patent/JP5301539B2/ja not_active Expired - Fee Related
- 2008-07-16 AU AU2008276057A patent/AU2008276057B2/en not_active Ceased
- 2008-07-16 US US12/173,864 patent/US7928230B2/en active Active
- 2008-07-16 AR ARP080103060A patent/AR067568A1/es unknown
- 2008-07-16 KR KR1020107003333A patent/KR20100051814A/ko not_active Application Discontinuation
- 2008-07-16 JP JP2010517122A patent/JP5318867B2/ja not_active Expired - Fee Related
- 2008-07-16 AR ARP080103061A patent/AR067569A1/es not_active Application Discontinuation
- 2008-07-16 PE PE2008001196A patent/PE20090888A1/es not_active Application Discontinuation
- 2008-07-16 CA CA2693444A patent/CA2693444A1/en not_active Abandoned
- 2008-07-16 PT PT08781867T patent/PT2170864E/pt unknown
- 2008-07-16 AT AT08781868T patent/ATE540945T1/de active
- 2008-07-16 AU AU2008276055A patent/AU2008276055B2/en not_active Ceased
- 2008-07-16 CN CN201310495045.6A patent/CN103550218A/zh active Pending
- 2008-07-16 EA EA201000210A patent/EA018709B1/ru not_active IP Right Cessation
- 2008-07-16 CN CN200880108168A patent/CN101801957A/zh active Pending
- 2008-07-16 DK DK08781867.0T patent/DK2170864T3/da active
- 2008-07-16 EP EP08781868A patent/EP2173737B1/en not_active Not-in-force
- 2008-07-16 NZ NZ582661A patent/NZ582661A/en not_active IP Right Cessation
- 2008-07-16 TW TW097127045A patent/TW200904439A/zh unknown
- 2008-07-16 BR BRPI0814428-1A2A patent/BRPI0814428A2/pt not_active IP Right Cessation
- 2008-07-16 WO PCT/US2008/070101 patent/WO2009012275A1/en active Application Filing
- 2008-07-16 ES ES08781867T patent/ES2371515T3/es active Active
- 2008-07-16 BR BRPI0815097A patent/BRPI0815097A2/pt not_active IP Right Cessation
- 2008-07-16 PT PT08781868T patent/PT2173737E/pt unknown
- 2008-07-16 ES ES08781868T patent/ES2378914T3/es active Active
- 2008-07-16 PL PL08781868T patent/PL2173737T3/pl unknown
- 2008-07-16 AT AT08781867T patent/ATE524460T1/de active
- 2008-07-16 DK DK08781868.8T patent/DK2173737T3/da active
- 2008-07-17 CL CL200802111A patent/CL2008002111A1/es unknown
- 2008-07-17 CL CL200802110A patent/CL2008002110A1/es unknown
2010
- 2010-01-08 ZA ZA2010/00151A patent/ZA201000151B/en unknown
- 2010-01-15 ZA ZA2010/00326A patent/ZA201000326B/en unknown
- 2010-01-15 CO CO10003756A patent/CO6160315A2/es unknown
- 2010-04-15 HK HK10103702.1A patent/HK1136298A1/xx not_active IP Right Cessation
- 2010-10-05 HK HK10109487.9A patent/HK1143136A1/xx not_active IP Right Cessation
2011
- 2011-03-07 US US13/041,564 patent/US8178561B2/en active Active
- 2011-06-14 US US13/159,497 patent/US8232404B2/en active Active
- 2011-11-02 HR HR20110806T patent/HRP20110806T1/hr unknown
- 2011-12-14 CY CY20111101241T patent/CY1112151T1/el unknown
2012
- 2012-03-07 HR HR20120221T patent/HRP20120221T1/hr unknown
- 2012-04-09 CY CY20121100343T patent/CY1112751T1/el unknown
- 2012-04-24 US US13/454,789 patent/US20120232048A1/en not_active Abandoned
- 2012-06-12 US US13/494,489 patent/US8513424B2/en active Active
2013
- 2013-07-10 JP JP2013144778A patent/JP2013237680A/ja not_active Withdrawn
- 2013-08-26 IL IL228120A patent/IL228120A0/en unknown

Also Published As

Publication number	Publication date
JP5318867B2 (ja)	2013-10-16
CA2693439A1 (en)	2009-01-22
US8178561B2 (en)	2012-05-15
WO2009012277A1 (en)	2009-01-22
US20120232048A1 (en)	2012-09-13
EP2173737B1 (en)	2012-01-11
TW200904440A (en)	2009-02-01
KR20100051814A (ko)	2010-05-18
AU2008276057B2 (en)	2013-01-31
US8232404B2 (en)	2012-07-31
US20120258959A1 (en)	2012-10-11
EA201000211A1 (ru)	2010-06-30
DK2170864T3 (da)	2012-01-16
PL2173737T3 (pl)	2012-06-29
PT2173737E (pt)	2012-03-19
ATE524460T1 (de)	2011-09-15
SI2173737T1 (sl)	2012-05-31
US7928230B2 (en)	2011-04-19
EP2170864A1 (en)	2010-04-07
ATE540945T1 (de)	2012-01-15
ES2371515T3 (es)	2012-01-04
ZA201000326B (en)	2011-03-30
CY1112751T1 (el)	2016-02-10
WO2009012275A1 (en)	2009-01-22
US8003796B2 (en)	2011-08-23
NZ582664A (en)	2012-03-30
CL2008002110A1 (es)	2008-10-24
CO6160315A2 (es)	2010-05-20
PE20090449A1 (es)	2009-04-18
JP2010533726A (ja)	2010-10-28
KR20100045471A (ko)	2010-05-03
PE20090888A1 (es)	2009-07-15
AU2008276055B2 (en)	2013-01-31
EA016595B1 (ru)	2012-06-29
US20090023702A1 (en)	2009-01-22
PL2170864T3 (pl)	2012-02-29
NZ582661A (en)	2012-03-30
DK2173737T3 (da)	2012-05-07
US20110245227A1 (en)	2011-10-06
HK1143136A1 (en)	2010-12-24
JP2013237680A (ja)	2013-11-28
EP2173737A1 (en)	2010-04-14
HK1136298A1 (en)	2010-06-25
TW200904439A (en)	2009-02-01
CN103550218A (zh)	2014-02-05
AR067568A1 (es)	2009-10-14
PT2170864E (pt)	2011-11-25
BRPI0814428A2 (pt)	2015-01-06
HRP20120221T1 (hr)	2012-04-30
EA201000210A1 (ru)	2010-06-30
ZA201000151B (en)	2011-03-30
EP2170864B1 (en)	2011-09-14
SI2170864T1 (sl)	2012-04-30
CA2693444A1 (en)	2009-01-22
EA018709B1 (ru)	2013-10-30
AU2008276057A1 (en)	2009-01-22
CY1112151T1 (el)	2015-12-09
US20090042919A1 (en)	2009-02-12
ES2378914T3 (es)	2012-04-19
IL228120A0 (en)	2013-09-30
AU2008276055A1 (en)	2009-01-22
CN101801956A (zh)	2010-08-11
CL2008002111A1 (es)	2008-10-24
AR067569A1 (es)	2009-10-14
US8513424B2 (en)	2013-08-20
JP2010533727A (ja)	2010-10-28
WO2009012275A9 (en)	2010-03-11
HRP20110806T1 (hr)	2011-11-30
CN101801957A (zh)	2010-08-11
US20110190327A1 (en)	2011-08-04
JP5301539B2 (ja)	2013-09-25
CN101801956B (zh)	2013-11-20

Legal Events

Date	Code	Title	Description
2018-07-31	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-11-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2482 DE 31-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0815097A2 (pt)	2018-07-24	agonistas de receptor acoplado à proteína g gpr119 de piridona
BRPI0820447A2 (pt)	2015-05-26	Agonistas do receptor de glicocorticóides
BRPI0806500A2 (pt)	2014-04-22	Agonistas gpcr de piperidina
ATE531710T1 (de)	2011-11-15	Piperidin-gpcr-agonisten
HRP20151108T1 (en)	2015-11-20	Nogo receptor antagonists
IL208919A0 (en)	2011-01-31	Gpr119 receptor agonists
EP2173174A4 (en)	2010-08-04	FARNESOID X RECEPTOR AGONISTS
EP2170072A4 (en)	2010-10-27	Farnesoid X RECEPTOR AGONISTS
GB0720390D0 (en)	2007-11-28	G-Protein coupled receptor agonists
ATE549350T1 (de)	2012-03-15	Neuropeptid-2-rezeptor-agonisten
GB0720389D0 (en)	2008-11-12	G-Protein Coupled Receptor Agonists
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
BRPI0910118A2 (pt)	2015-12-29	antagonistas de receptores do glucagon
GB0607196D0 (en)	2006-05-17	G-protein coupled receptor agonists
EP2151236A4 (en)	2013-01-16	G PROTEIN COUPLED RECEPTOR AGONIST
ATE509022T1 (de)	2011-05-15	Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
EP2079307A4 (en)	2010-09-15	FARNESOID RECEPTOR AGONISTS X
DE602006020447D1 (de)	2011-04-14	Niacin-rezeptoragonisten, zusammensetzungen mit de
BRPI0921815A2 (pt)	2018-10-09	compostos receptores de apj
EP2041120A4 (en)	2010-12-22	MELANOCORTIN RECEPTOR AGONISTS
DK2252581T3 (da)	2012-07-16	Kappa-selektiv opioidreceptorantagonist
BRPI0810926A2 (pt)	2014-11-04	Antagonista de crig
DK1989196T3 (da)	2013-04-15	Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
BRPI0820805A2 (pt)	2015-06-16	Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
ATE524458T1 (de)	2011-09-15	Als p2x7-rezeptor-antagonist wirkendes chinolinderivat